Generics Take a Bite of Eli Lilly Q3 Results

Before you go, we thought you'd like these...
Before you go close icon

Eli Lilly (NYSE: LLY) this morning reported disappointing third-quarter results as generic drugs took a toll on its sales.

The Indianapolis-based drug maker posted adjusted earnings per share (EPS) of $0.79 on revenues of $5.44 billion. In the same period a year ago, the company reported EPS of $1.13 on revenues of $6.15 billion. The quarter's results also compare to the Thomson Reuters consensus estimates for EPS of $0.83 and $5.62 billion in revenues.

The company's chairman and CEO said:

The third quarter was an eventful one for Lilly, as we gained a better understanding of several potential new medicines in our clinical pipeline, while maintaining focus on delivering solid financial results despite the loss of Zyprexa patent exclusivity.

Also, the company recognized a charge of $53.3 million in the quarter related to asset impairments associated with the decision to stop development of a delivery device platform.

Eli Lilly now expects full-year 2012 EPS to be in the range of $3.30 to $3.40 on revenue of between $21.8 and $22.8 billion. The Thomson Reuters consensus estimates call for EPS of $3.39 and $22.72 billion in revenues.

Shares are inactive in premarket trading but closed yesterday at $51.91. The 52-week range is $35.46 to $53.99.


Filed under: 24/7 Wall St. Wire, Drug companies, Earnings Tagged: LLY
Read Full Story

Markets

S&P 500 2,204.71 12.76 0.58%
DJIA 19,216.24 45.82 0.24%
NASDAQ 5,308.89 53.24 1.01%
DAX 10,714.44 29.61 0.28%
HANG SENG 22,675.15 169.60 0.75%
NIKKEI 225 18,360.54 85.55 0.47%
USD (per EUR) 1.07 0.00 -0.18%
USD (per CHF) 1.01 0.00 0.32%
JPY (per USD) 114.00 0.14 0.12%
GBP (per USD) 1.28 0.00 0.23%

From Our Partners